H. Lundbeck A/S reports real-world INFUSE study data at AAN 2026 showing improvements in migraine-related cognitive symptoms, including brain fog, with eptinezumab treatment.
Written By: Chikkula Pavan Kumar, PharmD
Reviewed By: Pharmacally Editorial Team
Lundbeck A/S has presented six-month real-world findings from the INFUSE study at the American Academy of Neurology Annual Meeting 2026, highlighting the broader burden of migraine beyond headache frequency and reporting improvements in patient-reported cognitive symptoms following treatment with eptinezumab.
Migraine is a complex neurological disorder associated with fluctuating symptoms and significant impairment in daily functioning and quality of life. While headache is its defining feature, cognitive symptoms such as “brain fog” remain underrepresented in research despite being commonly reported by patients.
The interim analysis of the INFUSE study shows that cognitive symptoms were highly prevalent among patients who had previously not responded adequately to anti-CGRP preventive therapies. At baseline, a substantial proportion of participants reported symptoms such as brain fog, difficulty making decisions, difficulty with complex tasks, and challenges with reading comprehension as moderately to extremely bothersome.
Following treatment with eptinezumab, more than half of participants reported improvements across these cognitive domains at six months, with some improvements observed as early as seven days after treatment initiation.
These findings indicate that preventive therapy may extend beyond reducing headache frequency to addressing broader functional impairments associated with migraine.
Amaal Starling noted that patients frequently describe migraine-related cognitive symptoms as highly disruptive to work, family life, and daily activities, and indicated that the observed improvements support a more comprehensive treatment approach, particularly for those with high disease burden despite prior therapies.
Damian Fiore, Vice President of Lundbeck US Medical Affairs, Neurology, stated that the INFUSE data provide insight into managing the full spectrum of migraine burden and may help inform treatment decisions.
INFUSE is a 12-month, prospective observational study conducted in the United States to evaluate the real-world effectiveness of intravenous eptinezumab in adults with migraine who have failed at least one prior anti-CGRP preventive treatment. Data are collected through patient-reported outcomes at multiple time points, focusing on overall improvement, headache frequency, and quality-of-life measures.
Eptinezumab (VYEPTI®) is a monoclonal antibody targeting calcitonin gene-related peptide and is administered as a 30-minute intravenous infusion every three months. Its efficacy and safety have been established in phase 3 trials, and it has been approved for the preventive treatment of migraine in multiple markets worldwide.
Overall, the findings reinforce the importance of evaluating non-headache symptoms in migraine care and suggest that addressing cognitive impairment may be an important component of improving patient outcomes.
Reference
About the Writer
Chikkula Pavan Kumar, Pharm.D is a Doctor of Pharmacy with a keen interest in clinical pharmacy, pharmacovigilance, and evidence-based practice. In his words, he is passionate about patient safety and translating complex medical information into clear, research-driven communication.